On March 17, www.cls.cn reported that AIM Vaccines announced on March 17 that it expects a significant reduction in losses for 2024, with revenue expected between RMB 1.25 billion and 1.3 billion, a 5%–9% year-on-year increase; net losses are expected to range from RMB 250 million to 290 million, reflecting an 85%–87% reduction in losses. This improvement is primarily due to reduced impairment losses and higher revenue from its hepatitis B vaccine. Previously, research report from Fosun International Securities projected a 47% CAGR for AIM's revenue from 2024 to 2027, with net profits expected to exceed RMB 1.52 billion by 2027.